HC Wainwright Has Pessimistic Outlook of DRTS Q2 Earnings

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Alpha Tau Medical in a research report issued to clients and investors on Wednesday, May 20th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.14) per share for the quarter, down from their prior estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.55) EPS.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

DRTS has been the subject of a number of other reports. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Piper Sandler raised their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday. LADENBURG THALM/SH SH raised their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Finally, Citigroup increased their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and an average price target of $11.50.

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $10.96 on Friday. The company has a 50-day moving average price of $7.96 and a two-hundred day moving average price of $6.52. The firm has a market capitalization of $964.59 million, a PE ratio of -16.36 and a beta of 1.11. Alpha Tau Medical has a twelve month low of $2.81 and a twelve month high of $11.62. The company has a quick ratio of 7.45, a current ratio of 7.79 and a debt-to-equity ratio of 0.09.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Envestnet Asset Management Inc. bought a new position in Alpha Tau Medical during the 3rd quarter valued at approximately $62,000. Levin Capital Strategies L.P. raised its position in Alpha Tau Medical by 6.3% in the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after buying an additional 12,200 shares during the last quarter. Bank of America Corp DE lifted its position in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Millennium Management LLC purchased a new position in shares of Alpha Tau Medical in the 3rd quarter worth $170,000. Finally, Mariner LLC boosted its position in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after purchasing an additional 80,129 shares during the last quarter. Institutional investors own 2.65% of the company’s stock.

Key Stories Impacting Alpha Tau Medical

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Alpha Tau Medical and maintained a $15 price objective, signaling continued confidence in the company’s longer-term growth outlook. Alpha Tau Medical (NASDAQ:DRTS) Receives “Buy” Rating from HC Wainwright
• Positive Sentiment: The firm’s target price suggests roughly 36.9% upside from the recent share price, which may be encouraging investors despite ongoing losses. Benzinga
• Neutral Sentiment: HC Wainwright also laid out multiple earnings estimates for 2026 and 2027, with losses of about $0.14 per share per quarter expected in the near term and FY2026 EPS of -$0.67, indicating the company is still not expected to be profitable soon.
• Negative Sentiment: The analyst trimmed several EPS forecasts, including Q2 2026, Q3 2026 and Q4 2026, and cut the FY2026 estimate to a larger loss than before, which could temper enthusiasm.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.